Compare ELTX & FEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | FEAM |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 56.9M |
| IPO Year | 2014 | 2022 |
| Metric | ELTX | FEAM |
|---|---|---|
| Price | $1.85 | $2.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $18.00 | $6.38 |
| AVG Volume (30 Days) | 344.5K | ★ 642.4K |
| Earning Date | 05-12-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.29 | ★ 63.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $0.90 |
| 52 Week High | $16.00 | $7.50 |
| Indicator | ELTX | FEAM |
|---|---|---|
| Relative Strength Index (RSI) | 26.56 | 70.68 |
| Support Level | $1.71 | $1.37 |
| Resistance Level | $3.32 | $4.00 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 26.12 | 86.45 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.